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1. Introduction
Soy bean trypsin inhibitor (SBTI) belongs to the family of serpins – serine protease inhibitors
widely distributed in the nature [Silverman G.A. et al., 2004; 21]. Serpins participate in the
regulation of proteopytic reactions underling very important physiological and pathological
processes such as digestion [16], blood clotting [3, 14, 17], immunity [44] apoptosis [36, 42],
inflammation [10], dystrophy [31], carcinogenesis [22, 11] and so on. Despite the apparent
importance of the correction of imbalances of the proteolysis in pathology, in fact only the
pancreatic trypsin inhibitor (aprotinin) is used more or less widely as a protease inhibitor
drug (Trasisol, Contrical, Gordox etc) in the treatment of some diseases [24, 13, 40]. Being
the animal protein aprotinin possesses substantial disadvantages [23, 12] and attempts to de‐
velop new drug on the base of plant or recombinant proteins or peptidomimetics are under‐
taken [35, 27]. SBTI is one of the candidates for such a role [34].
Among proteolytic processes hemostasis is of special importance because of the high fre‐
quency of it’s disturbances, accompanied many pathological processes and diseases [20, 18].
At first sight it looks strange to expect that plant protease inhibitor SBTI should influence
hemostasis in humans because blood clotting represents the cascade of proteolytic reactions
catalyzed by highly specific proteases [43]. However, results of the very early studies sup‐
port such possibility [26, 41]. The present study was aimed to investigate the influence of
SBTI and aprotinin on hemostasis using modern bioinformatics approach and classical in vi‐
tro methods. The concrete purposes of the study included:
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1. To establish the extent of structural homology, compare functional activities and evalu‐
ate potential targets of SBTI and aprotinin among the human proteases by bioinformat‐
ics (in silico) methods.
2. To investigate the influence of trypsin, SBTI and aprotinin on some indexes of blood
clotting, fibrilolysis and platelet aggregation as well as on the hemolytic activity of the
complement in vitro.
3. To elucidate the possibility of the regulation of the total proteolytic and tripsin-inhibit‐
ing activity of blood plasma in vivo by the consumption of soy foods enriched with soy
protein isolate (SPI) possessing thermo-stable fraction of SBTI.
2. The study of aprotinin and SBTI in silico
In silico methods (bioinformatics) entails the creation and advancement of databases, algo‐
rithms, computational techniques to solve formal and practical problems arising from the
management and analysis of biological data. One of the potential areas for exploiting these
methods is computational drug design. We used in silico methods in our study for the com‐
parison of structural homology, functional activities and evaluation of the potential targets
of SBTI and aprotinin among the human proteases.
From fifty databases we had browsed in the INTRNET nine contained information on apro‐
tinin and SBTI (Table 1). From these PDB (Protein Data Bank) and UniProt/Swiss-Prot were
the most informative and we used these databases in our study.
Database ID in the Database
Aprotinin SBTI
UniProt-Swiss-Prot
http://www.expasy.org BPT1_BOVIN (P00974) ITRA_SOYBN (P01070)
Blocks - most highly conserved regions of
proteins http://www.ebi.ac.uk P00974 IPR002160
COG - the database of Clusters of Ortologous
Groups of proteins
http://www.ncbi.nlm.nih.gov
Precursor P00974; NP_001001554; -
GTOP - Genomes TO Protein structures and
functions http://spock.genes.nig.ac.jp btau0:ENSBTAG00000017328 ?atha0:At1g17860.1
iProClass - an integrated, comprehensive and
annotated Protein Classification database
http://pir.georgetown.edu
P00974/BPT1_BOVIN; PIRSF001621 -
LIGAND - LIGAND chemical database for
enzyme reactions
50059016; 3809839; bta:616039;
100156830; Bt.32343;BPT1_BOVIN -
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Database ID in the Database
Aprotinin SBTI
http://www.pasteur.fr
MMDB - Molecular Modeling Data Base
http://www.ncbi.nlm.nih.gov P00974 (Precursor); 1QLQ0 1AVU
PDB - Protein Data Bank
http://www.rcsb.org 1OA6 1AVU; 1BA7
MEROPS (peptidases)
http://merops.sanger.ac.uk I02.001 I03.001
Table 1. Databases containing the information on aprotinin and SBTI.
 
2.1. The homology of the primary structures of SBTI and aprotinin
To investigate the homology of the primary structures of SBTI and aprotinin we used
BLAST (Basic Local Alignment Search Tool) algorithm, sequence alignment editor Bio Edit
5.0.9 and got information on these proteins from Protein Data Bank and Uni Prot using FAS‐
TA (Table 2), MOL and PDB format-files. The extent of homology of the total sequences of
SBTI and aprotinin, calculated by the method of the multiple paired alignment, makes up
10% (Figures 1 and 2). The low homology of the total sequences of should be attributed to
the different lengths of polypeptide chains these proteins – 58 amino acids in aprotinin [45]
and 181 in SBTI [39].
Traditional
abbreviation
Ala Asn Cys Asp Glu Phe Gly His Ile Lis Met
FASTA fromat A B C D E F G H I K M
Traditional
abbreviation
Asn Pro Gln Arg Ser Tre Val Trp Tyr Glu *
FASTA fromat N P Q R S T V W Y Z -
Table 2. Designation of aminoacids in FASTA format. *- symbol in FASTA format corresponds to the gap of unlimited
length
Comparison of the separate domains of SBTI and aprotinin reveals greater sequence similar‐
ity. Thus, the extent of homology of the N-terminal region of SBTI (5-60 amino acid resi‐
dues) and the sequence of aprotonin without last two amino acids makes up 21%. The
central region of SBTI (85-116 amino acid residues) and the region of aprotinin within 25-56
amino acids show 24% similarity. The highest extent of homology up to 35% is characteristic
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for C-terminal region of SBTI (132-181 amino acid residues) and aprotenin sequence without
six C-terminal amino acids.
Figure 1. The screen of the Bio Edit 5.0.9 with the results of calculation of homology of Aprotinin and SBTI. The identi‐
cal amino acids are marked with black and similar with gray. Amino acid sequence are represented in FASTA format.
Figure 2. Homological regions of Aprotinin and SBTI (according to Bio Edit 5.0.9). The identical amino acids are
marked with black and similar with gray.
2.2. Tertiary structures of SBTI and aprotinin
For the visualization of the 3D-structures of SBTI and aprotinin we used Chem Office 5.0
and Yasara 6.2.5 software. The files in MOL format, containing the information on the se‐
quences of these protease inhibitors, were imputed into Chem Office 5.0 software and con‐
verted in PDB format. The obtained PDB files were imputed into Yasara 6.2.5 software. The
results of the generation of the electronic 3D-structures of aprotinin and SBTI are presented
in Figure 3. Apparently there there is similarity of 3D-structures of these proteins.
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We failed to find molecular targets of SBTI and aprotinin because there was no necessary
software in free excess.
Figure 3. Electronic 3D-structures of SBTI and aprotinin. Left – model with the single surface (Chem Office 5.0). Right-
ribbon diagram (Yasara 6.2.5).
2.3. Spectra of biological activity of SBTI and aprotinin
The exploiting the PASS software shows four potential activities of aprotinin and three for
SBTI. Both SBTI and aprotinin may inhibit rennin as well as angiotensin- and endothelein-
converting enzymes according to the revealing of the possible biological activities of these
protease inhibitors by ISIS/Draw 2.4 and PASS Professional chemical structure drawing pro‐
grams (Figure 4). The possibility of exerting of such effects (drug-likeness) is nearly the
same in both protease inhibitors. Aprotinin may inhibit neutral endopeptidase, also. For all
the abovementioned activities probability of the activity (Pa) is higher than the probability of
the lack of activity (Pi). SBTI and aprotinin should not reveal serious toxicity, mutagenic,
carcinogenic and teratogenic effects according to in silico, in vitro and in vivo studies.
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Figure 4. Spectra of the biological activities of aprotinin and SBTI according to PASS software. Drug-Likeness – proba‐
bility of exerting the effect. Probability of the activity (Pa) and the lack of activity (Pi). The average accuracy of the prog‐
nosis makes up more than 85%.
3. The study of aprotinin and SBTI in vitro
In silico methods testify the common features in the primary structure, 3D-structures, func‐
tional activities of t SBTI and aprotinin and allow to propose that SBTI should influence
processes of hemostasis similar to aprotinin. To prove this assumption we studied the influ‐
ence of trypsin, SBTI and aprotinin on blood clottting, fibrilolysis and platelets aggregation
in vitro.
3.1. Trypsin-inhibitory activity of SBTI and aprotinin
We measured tyipsin-inhibitory activity of aprotinin, SBTI and low molecular weight pro‐
tease inhibitors (ε-aminocapronic acid and D-lysine) by their ability to inhibit BAEE-esterase
activity of the trypsin [33]. The results are presented in the table 3.
Trypsin inhibitor Aprotinin SBTI ε-aminocapronic acid D-lysine
Trypsin-inhibitory activity (IU/mg) 141±13 61±0,9 1,36±0,04 1,31±0,02
Trypsin-inhibitory activity
(IU/nmole)
0,922±0,085 1,23±0,02 - -
Table 3. Trypsin-inhibitory activity of aprotinin, SBTI, ε-aminocapronic acid and D-lysine.
Trypsin-inhibitory activity aprotinin, SBTI, ε-aminocapronic acid and D-lysine was meas‐
ured as their ability to inhibit BAEE-esterase activity of trypsin.
Tyipsin-inhibitory activity, calculated per mg of inhibitor, decrease down in the order: apro‐
tinin > SBTI > aminocapronic acid > D-lysine. Thus, tyipsin-inhibitory activity of aprotinin is
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2-times higher than similar activity of SBTI. However, taking into account that molecular
weight of SBTI (20100) is 3-times higher than molecular weight of aprotinin (6514), it should
be concluded that the trypsine-inhibitory activity of SBTI, calculated per mole of the inhibi‐
tor, should be nearly 1,5-times higher than trypsine-inhibitory activity of aptotinin. Tryp‐
sine-inhibitory activity of ε-aminocapronic acid and D-lysine when calculated per mole of
the inhibitor is negligibly low because of the low molecular weight.
3.2. The influence of SBTI and aprotinin on coagulation hemostasis
The following indexes, characterizing mainly the first and the second phases of blood clot‐
ting, were measured: prothrombin time (reflects activity of coagulation factors YII, V, X and
II), activated partial thromboplastin time (reflects activity of coagulation factors YII and
VIII), activated clotting time (a measure of the anticoagulation affects of heparin) and throm‐
bin time (time of the formation of fibrin clot). Results are summarized in the table 4.
Indexes
Time,sec
Plasma
(control)
(1)
Plasma +
trypsin
(2)
Plasma +
aprotinin
(3)
Plasma +
SBTI
(4)
Prothrombin time 20±0,9 13±0,9Р1-2<0,0001
21±0,9
Р1-3"/0,05
31±0,9
Р1-4<0,0001
Activated partial thromboplastin
time 36±1,7
3±0,9
Р1-2<0,0001
113±1,8
Р1-3<0,0001
105±2,7
Р1-4<0,0001
Thrombine time 16±0,9 2,5±0,5Р1-2<0,0001
24±0,9
Р1-3<0,0001
∞
Ativated clotting time 88±9,7 58±4,7Р1-2<0.002
157±12
Р1-4<0.0001
258±17
Р1-4<0.001
Euglobulin lysis time 400±34,7 182±7Р1-2<0,0001
No lysis of blood clot No lysis of blood clot
Table 4. The influence of trypsin, SBTI and aprotinin on the indexes of hemostasis in vitro. The final concentration of
trypsin in the incubation medium consisted of 0,01%, SBTI and aprotinin - 0,1%..
Prothrombin time decreases 33-35% in the presence of trypsin from 20±0,9 to 13±0,9 sec, in‐
creases insignificantly in the presence of aprotinin and increases 1,5-times up to 31±0,9 sec in
the presence of SBTI. Activated partial thromboplastin time sharply decreases by trypsin
from 36±1,7 sec in the control samples to 3,0+0,9 sec and increases 3-times by aprotinin
(113±1,8 sec) and SBTI (105±2,7 sec). The changes of the activated clotting time under the in‐
fluence of trypsin, aprotinin and SBTI are similar. Thrombin time decreases nearly 7-fold in
the presence of trypsin from 16±0,9 to 2,5±0.5 sec and increases on 50% by aprotinin to
24±0,9 sec. SBTI completely blocked the formation of fibrin clot at least within 10 min. Simi‐
lar effects trypsin and it’s inhibitors exerts on fibrinolysis. Euglobulin lysis time (factor XII–
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callicrein-dependent fibrinolysis) decreases 60% by trypsin from 400±35 to 182±7 sec. Aptoti‐
nin and SBTI in the abovementioned concentrations entirely inhibit the lysis of fibrin clot
(Table 4).
3.3 The influence of SBTI and aprotinin on platelet aggregation
Results of the study of the influence of SBTI and aprotinin on platelets aggregation are pre‐
sented in the table 5 and Figures 5-8.
Plasma
(control) 
(1)
Plasma +
aprotinin
(2)
Plasma +
SBTI
(3)
Plasma + trypsin
(4)
 
Reversible (ADP)
ТМА
 
 22±1,8
 55±4,7
 
14±0,9 Р1-2<0,01
55±4,7
 
15±0,9 Р1-3<0,01
55±4,7
 
34±0,9 Р1-4<0,01
65±15
Two-phase (ADP):
Fist phase
МА
ТМА
Second phase
МА
ТМА
 
 
48±1,8
85±4,7
 
70±2
350±9,2
 
 
35±0,9 Р1-2<0,01
68±10,5
 
56±2 Р1-2<0,02
325±9,2
 
 
34±1 Р1-3<0,01
70±9
 
58±1 Р1-3<0,05
320±9,3
 
 
57±3 Р1-4<0,01
80±10
 
99±1 Р1-4<0,02
310±9,2
Irreversible (ADP)
МА
ТМА
 
49±0,9
400±18
 
33±0,9 Р1-2<0,02
410±9,3
 
29±0,9 Р1-3<0,02
410±9,3
 
100 Р1-4<0,001
210±26,4of
Two-phase (adrenalin):
Fist phase
МА
ТМА
Second phase
МА
ТМА
 
 
23±0,9
110±9,3
 
47±2,4
390±9,3
 
 
16±1,8 Р1-2<0,02
125±13,1
 
44±2 Р1-2"/0,05
430±18
 
 
16±1,8 Р1-3<0,02
125±13,1
 
44±1,8 Р1-3"/0,05
430±18
 
 
32±0,9 Р1-4<0,01
130±9,3
 
55±0,9 Р1-4<0,02
435±16,2
Table 5. The effects of aprotinin, SBTI and trypsin on the aggregation of platelets initiated by ADP (reversible, two-
phase and irreversible aggregation) and adrenalin (two-phase aggregation). MA – maximum aggregation
(transmittance, %), ТМА – time of accomplishment of maximum aggregation (sec).
The effects of trypsin, SBTI and aprotinin on the aggregation of platelets initiated by ADP
(reversible, two-phase and irreversible aggregation) and adrenalin (two-phase aggregation)
are similar to their effects on blood coagulation and fibrinolysis. Trypsin increases platelet
aggregation (the increase of the maximum of all types of aggregation and decrease of maxi‐
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mum aggregation time of irreversible ADP-initiated aggregation). SBTI and aprotinin re‐
veals anti-aggregation effect manifested by the decrease of maximum aggregation.
Figure 5. ADP-initiated reversible aggregation of platelets in the presence of aptotinin, SBTI and trypsin in vitro. The
platelet aggregation was initiated by the addition of the 5 mkM ADP. 1 – controle; 2 – aprotinin - 1%; 3 – SBTI - 1%; 4
– trypsin – 0,1%.
Figure 6. ADP-initiated two-phase aggregation of platelets in the presence of aptotinin, SBTI and trypsin in vitro. The
platelet aggregation was initiated by the addition of the 5 mkM ADP. 1 – controle; 2 – aprotinin - 1%; 3 – SBTI - 1%; 4
– trypsin – 0,1%.
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Figure 7. ADP-initiated irreversible aggregation of platelets in the presence of aptotinin, SBTI and trypsin in vitro. The
platelet aggregation was initiated by the addition of the 25 mkM ADP. 1 – controle; 2 – aprotinin - 1%; 3 – SBTI - 1%; 4
– trypsin – 0,1%.
Figure 8. Adrenalin-initiated two-phase aggregation of platelets in the presence of trypsin, aptotinin and SBTI in vitro.
The platelet aggregation was initiated by the addition of the 25 mkM adrenalin. 1 – controle; 2 – trypsin - 0,1%; 3 –
aprotinin - 1%; 4 – SBTI - 1%.
So, the results of in vitro experiments proves the ability of SBTI to influence the hemostatsis
predicted by the in silico studies.
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3.4. The influence of SBTI and aprotinin on the hemolytic activity of the complement
Limited cascade proteolysis underlies the activation of the complement system, which in‐
cludes nearly 20 individual proteins [30, 37]. Majority of these proteins belongs to the serine
protease family (subunits C1r and C1s, С3/С5-cinvertase of the classical way of activation,
factors I and D) [15]. While complement system does not have direct relation to hemostasis
and targeted on alien cells and microorganisms, in some conditions complement system
may play a role in the disruption of intrinsic cells of the organism and among them blood
cells [15, 37]. Because of this we investigated the influence of trypsin, SBTI and aprotinin on
the hemolytic activity of the complement assuming that SBTI and aprotinin may retard he‐
molysis of red blood cells by inhibiting activation of some components of the complement
system. Results are presented in the table 6 and Figures 9-10.
Lag-phase (min) Total time of hemolysis, including lag-
phase (min)
Control (1) 3,5±0,5 8,5±1,5
Aprotinin (1%) (2) 3,2±0,15 Р1-2"/0,05 7,25±0,25 Р1-2"/0,05
SBNI (1%) (3) 3,2±0,15 Р1-3"/0,05 7,25±0,25 Р1-3"/0,05
Trypsin(0,01%) (4) 4,25±0,25 Р1-4<0,02 15,5±0,5 Р1-4<0,02
Table 6. The influence of aprotinin, SBTI and trypsin on the hemolytic activity of complement in vitro
Figure 9. The hemolytic activity of the complement in the presence of aprotinin, SBTI and trypsin in vitro. The lag-
phase is not shown. 1 – controle; 2 – aprotinin - 1%; 3 – SBTI - 1%; 4 – trypsin – 0,1%.
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Figure 10. The hemolytic activity of the complement in the presence of different concentrations of trypsin in vitro. The
lag-phase is not shown.
SBTI and aprotinin in the final concentrations 0,001-0,1% do not influence hemolysis time
and the only statistically insignificant effect consists of small decrease of lag-phase from
3,5±0,3 to 3,2±0,15 min (p>0,05) and total time of hemolysis from 8,5±1,5 to 7,25±0,15 min
(p>0,05). Trypsin suppresses the hemolytic activity of the complement in the concentration-
dependent manner. In the presence of 0.0001% and 0,001% trypsin the lag-phase of the he‐
molysis increases to 4,25±0,25 min (p<0,02) and total time of hemolysis to 11,5±0,5 min
(p<0,02) and 15,5±1,6 min (p<0,01), respectively. 0,01% trypsin entirely blocks the hemolysis.
The inhibiting effect of trypsin should be attributed to the disruption of С3 component of
the complement system.
Thus, the results obtained show that aprotinin and SBTI in the abovementiioned concentra‐
tions do not influence the hemolytic activity of the complement.
4. The influence of the consumption of soy priotein isolate by healthy
persons on the indexes of proteolysis in the blood serum
Soya is cultivated as a foodstuff, having favorable effect on human health, more than 3000
years [28]. Within the last decades soy foods have started to be used in Europe, USA and in
Russia as dietotherapy means at a number of diseases [6, 29]. In particular, we have shown
the cholesterol-lowering effect of soy protein, resulting from the consumption of SPI en‐
riched cookies by persons with modern hypelipidemia [7, 9]. The consumption of soy foods
is followed by the antioxidant effect [Santana et al., 2008, 8, 9] due to the high antioxidant
content in these foods [2, 9]. Antioxidant effect is important for the treatment of diseases fol‐
lowed by the development of the oxidative stress [1, 38].
The other possible use of soy foods in dietotherapy may be the correction of disturbances of
proteolytic processes. Activation of the tissue proteolysis accompanies different diseases
and pathological processes [34]. Soy protein foods contain Bouman-Birk type trypsin inhibi‐
tor – SBTI [4]. This protease inhibitor has been officially recognized as a component of food‐
stuff [25]. There are data showing the possibility of absorbtion of SBTI in the intestin after
the consumption of soy protein foods [22]. So, it seams reasonable to assume that the con‐
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sumption of soy foods will follow anti-proteolytic effect. Because of this it was interesting to
elucidate whether prolonged consumption of the cookies enriched with soy protein isolate
(SPI) will influence total proteolytic and trypsin-inhibiting activity of the blood plasma in
humans or not?
4.1. Tripsin-inhibiting activity of SPI
According to the characteristics, specified by manufacturer, protein content of SPI consists
of 90%. From this 10% belongs to protease inhibitors [32]. Within the processing of soy
beans into SPI the former are expoused to high temperatures, which inactivates the major
part of soy proteins. However, about 5-20 % of SBTI are represented by the thermostable
fraction [19, 22]. The measurement of the trypsin-inhibiting activity of SPI shows that tryp‐
sin-inhibiting activity of SPI consists of 1,4±0,1 IU/mg of SPI. For example 1 mg of pure SBTI
possesses activity equal nearby 60 IU. Thus, the active SBTI makes up 2,7% from SPI mass.
4.2. The influence of the consumption of SPI by healthy persons on the total proteolytic
and trypsin inhibiting activity of blood serum
30 adult people aged 35-67 years without the expressed signs of chronic diseases consumed
cookies, enriched with SPI (30% protein content), for two months [7]. Fasting blood samples
were drawn before and after the dietary treatment. Serum samples were frozen and ana‐
lyzed for total proteolytic (BAEE-esterase activity) and tripsin-inhibiting activity [33]. Daily
intake of 100g of cookies corresponds to consumption of 30g of SPI and about 0,85g of the
active SBTI (nearly 52 00 IU). The total consumption of SPI for two months consists of 1,8 kg
or 50 g of an active SBTI. Twenty-eight participants (19 females and 9 males) could complete
the trial. Results are presented in the table 7.
Total proteolytic activity
(relative units) Trypsin-inhibitory activity (IU/ml)
Before the
consumption 0,343±0,010 113±3,6
After the
consumption
0,282±0,008
р<0,05
137±5,3
р<0,01
Table 7. Total proteolytic and trypsin-inhibitory activity of blood serum of healthy persons before and after two
months consumption of soy protein isolate.
Total proteolytic activity of blood serum was measures as serum BAEE-esterase activity and
trypsin-inhibitory activity by inhibiting by serum of BAEE-esterase activity of trypsin.
Two months long SPI consumption was followed by 18% decrease of total proteolytic activi‐
ty of blood serum from 0,343±0,010 to 0,282±0,008 relative units (р<0,05) and by 21% increase
of trypsin-inhibiting activity from 113±3,6 to 137±5,3 IU/ml ( р<0,01). The results obtained
show possibility of the regulation of proteolysis in vivo by the consumption of soy foods.
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5. Discussion
The disturbances of the hemostasis accompany many pathological processes and diseases
[20, 18]. Both blood clotting and fibrinolysis represents the cascade of proteolytic reactions
catalyzed by highly specific proteases [43]. To correct disturbances of the fibrinolysis as well
as imbalances of the other proteolytic processes the animal trypsin inhibitor aprotinin is
used as a drug (Trasisol, Contrical, Gordox etc) [24, 13, 40]. The effectiveness of the aprotinin
in the treatment of some diseases has been questioned recently because of it’s substantial
disadvantages [23, 12]. Following consultation with the German Federal Institute for Drugs
and Medical Devices, the U.S. Food and Drug Administration, Health Canada, and other
health authorities, the producer of Trasilol - Bayer announced in 2007 that it has elected to
temporarily suspend worldwide marketing of Trasylol® (aprotinin injection) until final re‐
sults from the Canadian BARTtrial can be compiled, received and evaluated. Information re‐
garding the decision has been posted to Bayer’s websites [5]. Because of this attempts to
develop new protease inhibitor drug are undertaken [35, 27]. One of the candidates for such
a role is plant protease inhibitor - SBTI.
In the present study we exploited the advantages of the modern bioinformatics for establish‐
ing the extent of structural homology, comparing functional activities and evaluating poten‐
tial targets of SBTI and aprotinin among the human proteases. The results of in silico study
testifies apparent homology of SBTI and aprotinin manifested by the common features in
the primary structure, 3D-structures, functional activities of these proteins and allow us to
propose that SBTI should influence processes of hemostasis similar to aprotinin. The investi‐
gation of the influence of SBTI and aprotinin on coagulation and thrombocyte hemostasis by
in vitro methods prove this assumption and show that both proteins inhibit blood clotting,
fibrinolusis and platelet aggregation which is evident from the increase of prothrombin
time, activated partial thromboplastin time, activated clotting time, thrombin time and in‐
hibition of fibrinolysis. We investigated the influence of SBTI and aprotinin on the hemolytic
activity of the complement assuming that SBTI and aprotinin may retard hemolysis of red
blood cells by inhibiting activation of some components of the complement system. Howev‐
er, both inhibitors do not influence hemolysis time.
While the major part of SBTI is disrupted by heating, nearly 20% of inhibitor are thermosta‐
ble and remains active in soy foods [19]. Part of the consumed SBTI are absorbed in the intestine
after the consumption of soy foods [22]. Because of this we elucidated whether prolonged
consumption of the cookies, enriched with SPI, will influence total proteolytic and trypsin-
inhibiting activity of the blood plasma in humans or not? Daily intake of 100g of cookies
corresponds to consumption of about 0,85g of the active SBTI. The total consumption of SBTI
for the study period consists of 50 g of an active inhibitor. The consumption of 100 g of cookies
daily for two months was followed by 18% decrease of total proteolytic activity of blood serum
and by 21% increase of trypsin-inhibiting activity. The results obtained testify possibility of
the soft regulation of proteolysis in vivo by the consumption of soy foods.
At first, the ability of SBTI to inhibit blood clotting was shown more than half a centaury ago
[26, 41]. However, these results had no any practical consequences and in fact were forgot‐
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ten for a long time. Our study represent new attempt to revive interest to SBTI as possible
protease inhibiting drug.
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